

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/719,493		ATTY. DOCKET NO.: C1039.70021US01		
				FILING DATE: November 21, 2003		CONFIRMATION NO.: 3218		
				APPLICANT: Arthur M. Krieg et al.				
				GROUP ART UNIT: 1643		EXAMINER: Anne Gussow		
Sheet	1	of	2					

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		7,795,235	B2	Krieg et al.	09-14-2010
		7,807,803	B2	Krieg et al.	10-05-2010
		2010-0166780	A1	Debelak et al.	07-01-2010

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		AGRAWAL et al., Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7595-9.	
		AGRAWAL et al., Pharmacokinetics of antisense oligonucleotides. Clin Pharmacokinet. 1995 Jan;28(1):7-16.	
		AGRAWAL et al., Antisense oligonucleotides: towards clinical trials. Trends in Biotechnology. 1996;14:376-87.	
		BRODY et al., In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol. 2010 Oct 1;28(28):4324-32. Epub 2010 Aug 9.	
		FLIEGER, Testing drugs in people – FDA special issue on drug development. FDA Consumer Special Report. January 1995. 7 pages. Last accessed online on November 14, 2005 at http://www.fda.gov/fdac/special/newdrug/testing.html .	
		HOFMANN et al., Phase I evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother. 2008 Jun;31(5):520-7.	
		KIM et al., TLR9 Agonist Immunomodulator Treatment of Cutaneous T-Cell Lymphoma (CTCL) with CPG7909. Blood (ASH Annual Meeting Abstracts). Nov 2004;104(11):Abstract #743.	
		LEONARD et al., Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin Cancer Res. 2007 Oct 15;13(20):6168-74.	
		LINK et al., Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J Immunother. 2006 Sep-Oct;29(5):558-68.	
		MANEGOLD et al., Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008 Aug	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/719,493		ATTY. DOCKET NO.: C1039.70021US01			
				FILING DATE: November 21, 2003		CONFIRMATION NO.: 3218			
				APPLICANT: Arthur M. Krieg et al.					
				GROUP ART UNIT: 1643		EXAMINER: Anne Gussow			
Sheet	2	of	2						

		20;26(24):3979-86.	
		PASHENKOV et al., Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol. 2006 Dec 20;24(36):5716-24.	
		SPEISER et al., Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest. 2005 Mar;115(3):739-46.	
		TOKUNGA et al., How BCG Led to the Discovery of Immunostimulatory DNA. Jpn J Infect Dis. 1999;52:1-11.	
		VLASSOV et al., In Vivo pharmacokinetics of oligonucleotides following administration by different routes. CRC Press, Inc. Chapter 5. 1995:71-83.	

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR § 1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR § 1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR § 1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. § 120.]